Pfizer announced that the Hong Kong Department of Health (DoH) has approved its 20-valent Pneumococcal Conjugate Vaccine (PCV20) for active immunization in infants, children, and adolescents aged 6 weeks to less than 18 years. This approval follows the vaccine’s prior authorization for adults aged 18 years and older in April 2023.

PCV20 offers the broadest serotype coverage of any pediatric pneumococcal conjugate vaccine, protecting against 20 serotypes associated with invasive pneumococcal disease, pneumonia, and acute otitis media. This milestone further advances Pfizer's pediatric pneumococcal vaccine portfolio, which has been shaped by over two decades of innovation and leadership.

"The updated approval of PCV20 now offers parents an additional choice to help their children fight against 20 pneumococcal serotypes in circulation," said Krishnamoorthy Sundaresan, General Manager, Pfizer Hong Kong, and Macau. "This important approval underscores Pfizer's commitment to providing innovative solutions that protect infants and families from life-threatening infections."

Addressing a Significant Public Health Need

Pneumonia is a leading cause of death in Hong Kong, responsible for an average of 31 deaths daily in 2023. It is also one of the most common reasons for hospitalization[vii]. Among children under five years old, pneumonia caused by Streptococcus pneumoniae remains a significant concern, accounting for 14% of global deaths in this age group in 2019.

PCV20 builds on the success of PCV13 by adding seven new serotypes (8, 10A, 11A, 12F, 15B, 22F, and 33F), which are associated with antibiotic resistance, increased disease severity, invasive potential, and prevalence in pediatric pneumococcal cases. This enhanced protection positions PCV20 as a vital tool in combating pneumococcal disease and safeguarding public health.